Asia-Pacific Migraine Treatment Market, By Types (Episodic, Migraine with Aura, Chronic and Others), Treatment (Acute/Abortive Treatment, Preventive/ Prophylactic Treatment, Non-Pharmacological Therapies and Devices), Route of Administration (Oral, Parenteral, Nasal Sprays and Others), Product Type (Prescription and Over The Counter), Type (Branded and Generic), End User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies And Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Migraine is a common and incapacitating brain disorder. Headache is responsible for 4.4 percent of all general practice visits, nearly 5% of all medical hospital admissions, and more than 20% of neurology outpatient consults. Migraine affects approximately 20% of people at some point in their lives; epidemiological studies show that 4.5 percent of the population in Western Europe suffers from headaches at least 15 days per month, while global studies suggest that about 1% of the world's population are suffering from chronic migraine.
Data Bridge Market Research analyses that the migraine treatment market which was USD 2.38 billion in 2021, would rocket up to USD 4.67 billion by 2029, and is expected to undergo a CAGR of 8.80% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Types (Episodic, Migraine with Aura, Chronic and Others), Treatment (Acute/Abortive Treatment, Preventive/ Prophylactic Treatment, Non-Pharmacological Therapies and Devices), Route of Administration (Oral, Parenteral, Nasal Sprays and Others), Product Type (Prescription and Over The Counter), Type (Branded and Generic), End User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies And Others)
|
|
Countries Covered
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC)
|
|
Market Players Covered
|
Pfizer Inc. (U.S), Eli Lilly and Company (U.S), Amgen Inc. (U.S), GSK plc. (U.K), Novartis AG (Switzerland), Bayer AG (Germany), Allergan (Ireland), Abbott (U.S), Allodynic Therapeutics, LLC (U.S), AOBiome (U.S), AstraZeneca (U.K), Aurobindo Pharma USA (U.S), Bausch Health Companies Inc. (Canada), Biohaven Pharmaceuticals (U.S), Boehringer Ingelheim International GmbH (Germany), Catalent, Inc (U.S), Dr. Reddy’s Laboratories Ltd. (India), Impel Pharmaceuticals Inc. (U.S), H. Lundbeck A/S (Denmark), Merck & Co., Inc (U.S)
|
|
Market Opportunities
|
|
Market Definition
Migraine is a life-threatening neurological condition marked by recurring attacks of severe throbbing head pain that can last up to three days. The headaches can last anywhere from four hours to three days and are usually unilateral. Other symptoms that are usually associated with pain include nausea, vomiting, increased sensitivity to light (photophobia), increased sensitivity to sound (phonophobia), tingling or numbness in the extremities or legs, sweating, and diarrhoea.
Migraine Treatment Market Dynamics
Drivers
- Rise in the prevalence and diagnosis of migraine
A huge increase in migraine is a primary factor driving market expansion. Aside from that, the market is benefiting from improved reimbursement policies for migraine treatments and the rising demand for precision medicines. Additionally, rising demand for electrical nerve stimulating devices to treat migraines and the expected approval of new classes of late-stage pipeline drugs with higher clinical efficacy, such as the introduction of calcitonin gene-related peptide (CGRP) monoclonal antibodies, are propelling market growth.
- Significant advances are currently being made in the prophylactic treatment of CM
These significant advancements should prompt us to reconsider our approach to this devastating disease and empower us to remain vigilant and continue scientific clinical research, keeping in mind that only a common, shared clinical and scientific management strategy will improve CM detection, distinguish phenotypes and biological markers, shed light on neglected clinical governance areas, provide individualised healthcare and tailored therapy, and optimise the allocation of economic resources. It is our responsibility to guarantee that novel and evolving therapeutic options, such as OBT-A and anti-CGRP monoclonal antibodies, are fully utilised as part of a broader preventative culture in order to substantially reduce the human, societal, and economic consequences of this fatal disease.
- Increase in focus of vendors on the emerging markets
Asia-Pacific and Latin America and the Caribbean are likely to drive market growth. Due to increased demand for better healthcare facilities and advances in healthcare infrastructure, Asia-Pacific is expected to grow significantly in the future. Furthermore, because the developed markets are somewhat saturated, this region presents exceptional potential for venture capitalists and investors.
Opportunities
Raised research and development (R&D) expenditure in migraine therapy leads to pipeline goods, which will result in manufacturers putting new medicines into the market, raising demand, and technological advancement for the treatment of acute migraine has increased demand. Several research projects are now underway, which will likely give manufacturers a competitive advantage in generating new, innovative, and enhanced migraine treatment drugs as well as other migraine therapy prospects.
Restraints/Challenges
However, use of alternative therapies such as homeopathy and limitations of current migraine therapies, a decline in clinical visits and procedural treatment of migraines due to social distancing norms expected to restraint the market growth in the forecast period 2022 to 2029.
This migraine treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the migraine treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Migraine Treatment Market
The neurologic indications of COVID-19 indicate that the virus entered the nervous system by the olfactory groove or the circulation. Numerous studies have connected COVID-19 mortality to cardiac and pulmonary disorders. Migraine also produces a higher rate of vascular problems, putting migraine sufferers at a higher risk of unsatisfactory COVID-19 results. COVID-19 acute symptoms such as fever, insomnia, and dehydration might set to a migraine episode. COVID-19 headaches were described as pulsing, pressing, or stabbing. They were mostly bilateral, lasted longer, were resistant to analgesia, and were more common in men. Migraine sufferers are especially sensitive to the pandemic's long-term and indirect effects, such as depression, tiredness from the virus, and anxiety.
Recent Development
- In February 2022, Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, received a favourable opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), according to Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. It is recommended for marketing authorization as the 75 mg dose of Rimegepant (available as an orally dissolving tablet) for the acute treatment of migraine with or without aura in adults, as well as the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.
- In January 2022, Elyxyb (celecoxib oral solution) is a novel fast-acting liquid from BioDelivery Sciences. It's one of the first FDA-approved ready-to-use oral treatments for individuals suffering from acute migraine with or without aura.
Asia-Pacific Migraine Treatment Market Scope
The migraine treatment market is segmented on the basis of type, treatment, route of administration, product, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Types
- Episodic
- Migraine with Aura
- Chronic
- Others
Treatment
- Acute/Abortive Treatment
- Preventive/prophylactic Treatment
- Non-Pharmacological Therapies and Devices
Route of Administration
- Oral
- Parenteral
Product
- Prescription
- Over The Counter
Type
- Branded
- Generic
End-User
- Hospitals
- Clinics
- Homecare
- Others
Distribution Channel
- Hospital-Based Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Migraine Treatment Market Regional Analysis/Insights
The migraine treatment market is analysed and market size insights and trends are provided by country, type, treatment, route of administration, product, distribution channel and end-user as referenced above.
The countries covered in the migraine treatment market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
China is dominating the Asia-Pacific migraine treatment market because the pharmaceutical industry is one of leading industries in the country with growing number of investors. Focus on organic growth, rising urbanisation, and changes in disposable income are all major variables influencing the market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The migraine treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for migraine treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the migraine treatment market. The data is available for historic period 2010-2020.
Competitive Landscape and Migraine treatment Market Share Analysis
The migraine treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to migraine treatment market.
Some of the major players operating in the migraine treatment market are:
- Pfizer Inc. (U.S)
- Eli Lilly and Company (U.S)
- Amgen Inc. (U.S)
- GSK plc. (U.K)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Allergan (Ireland)
- Abbott (U.S)
- Allodynic Therapeutics, LLC (U.S)
- AOBiome (U.S)
- AstraZeneca (U.K)
- Aurobindo Pharma USA (U.S)
- Bausch Health Companies Inc. (Canada)
- Biohaven Pharmaceuticals (U.S)
- Boehringer Ingelheim International GmbH (Germany)
- Catalent, Inc (U.S)
- Dr. Reddy’s Laboratories Ltd. (India)
- Impel Pharmaceuticals Inc. (U.S)
- H. Lundbeck A/S (Denmark)
- Merck & Co., Inc (U.S)
SKU-